Home/Pipeline
Program
PreclinicalPhase 1Phase 2Phase 3FiledApproved
Next milestoneCLV-122berolumab-cvraHER-low breast cancer (first line)Oncology · ADC
Regulatory decision Q2 2027
CLV-219teravolumabHidradenitis suppurativaImmunology · Antibody
Regulatory decision H2 2027
Pipeline as of September 30, 2026. Programs and data are fictional.